Investors
To download our documents
OSE Immunotherapeutics is listed since 30th March 2015 on the regulated market of Euronext Paris
FR0012127173
OSE
Continuous
21,651,101 shares as of September 27, 2023
Eligible to Long-Only Deferred Settlement Service
Annual financial results 2023
General shareholders' meeting
Half-year results 2024